NICE issued a statement saying that a key uncertainty in estimating Enhertu’s cost-effectiveness was how much longer people on Enhertu live compared with those receiving standard treatment in ...

Management aims to mitigate these risks by accelerating ENHERTU’s market penetration. Vaccine sales uncertainties and high cost of sales due to product mix remain potential pressure points on ...

The agency said the two companies had failed to put forward "a cost-effective price that would have enabled us to recommend Enhertu as value for money for the taxpayer" in the final round of ...

Enhertu is a combination of a chemotherapy drug and targeted therapy. This type of therapy differs from immunotherapy. Doctors prescribe Enhertu for certain types of breast, lung, and other ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...